China SXT Pharmaceuticals (SXTC) Cash & Equivalents (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Cash & Equivalents of $28.2 million for Q1 2026, up 55.42% year-over-year from $18.1 million in Q1 2025, and up 33.12% quarter-over-quarter from $21.2 million in Q3 2025.
China SXT Pharmaceuticals (SXTC) Cash & Equivalents (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $28.2 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 55.42% year-over-year to $28.2 million; the TTM figure through Mar 2026 stood at $28.2 million (up 55.42% YoY), while the FY2026 annual figure was $28.2 million, up 55.42% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $28.2 million, up from $21.2 million in the prior quarter.
- The five-year high for Cash & Equivalents was $28.2 million in Q1 2026, with the low at $12.1 million in Q1 2024.
- The 5-year median for Cash & Equivalents is $17.4 million (2023), against an average of $18.2 million.
- The sharpest annual moves came in 2024 and 2026: Cash & Equivalents tumbled 30.46% in 2024, then surged 55.42% in 2026.
- China SXT Pharmaceuticals' Cash & Equivalents stood at $15.6 million in 2022, then gained by 11.55% to $17.4 million in 2023, then increased by 6.59% to $18.5 million in 2024, then rose by 14.33% to $21.2 million in 2025, then surged by 33.12% to $28.2 million in 2026.
- Business Quant data shows SXTC's Cash & Equivalents at $28.2 million in Q1 2026, $21.2 million in Q3 2025, and $18.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 164.00 Mn |
| 10 | China SXT Pharmaceuticals | 32,029.92 | -28.14 Mn | - | 28.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.18 Mn |
| Sep 30, 2025 | 21.17 Mn |
| Mar 31, 2025 | 18.13 Mn |
| Sep 30, 2024 | 18.51 Mn |
| Mar 31, 2024 | 12.08 Mn |
| Sep 30, 2023 | 17.37 Mn |
| Mar 31, 2023 | 17.37 Mn |
| Sep 30, 2022 | 15.57 Mn |
| Mar 31, 2022 | 15.57 Mn |
| Sep 30, 2021 | 13.36 Mn |
| Mar 31, 2021 | 13.36 Mn |
| Sep 30, 2020 | 10.35 Mn |
| Mar 31, 2020 | 7.29 Mn |
| Sep 30, 2019 | 9.29 Mn |
| Mar 31, 2019 | 9.29 Mn |
| Sep 30, 2018 | 383,606.00 |
| Mar 31, 2018 | 657,767.00 |